Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7692047 | 0.81 | TSHR (0.59) | TSHRTP53THRBALDH1A1MEN1 | |
| SCHEMBL15903204 | 0.77 | MAPK14 (0.41) | TP53ALDH1A1L3MBTL1HTTTRPM8 | |
| SCHEMBL16654075 | 0.77 | TSHR (0.54) | TSHRTP53THRBALDH1A1NPC1 | |
| SCHEMBL3480428 | 0.76 | KMT2A (0.43) | TSHRMEN1KMT2AL3MBTL1TRPM8 | |
| SCHEMBL15904408 | 0.74 | TSHR (0.54) | TSHRTP53THRBALDH1A1NPC1 | |
| SCHEMBL17892578 | 0.74 | MAPK14 (0.45) | TSHRTP53ALDH1A1NPC1L3MBTL1 | |
| SCHEMBL15903063 | 0.73 | MAPK14 (0.40) | TSHRHTTTRPM8POLQ | |
| SCHEMBL5225088 | 0.70 | TSHR (0.59) | TSHRTP53THRBALDH1A1NPC1 | |
| SCHEMBL17675195 | 0.70 | TSHR (0.59) | TSHRTP53THRBALDH1A1NPC1 | |
| SCHEMBL15903294 | 0.69 | MAPK14 (0.42) | ALDH1A1MEN1KMT2AL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220409-A1 | Flecainide synthesis | MCDANIEL WILLIAM C | 2004-11-04 | — | — | US | claimed |
| WO-2002066413-A1 | FLECAINIDE SYNTHESIS | NARCHEM CORPORATION (US) | 2002-08-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220409-A1 | Flecainide synthesis | KCNH1, CYP3A43, CYP2F1 | TSHR 245/4885TP53 4843/4885THRB 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.